Oncotarget

Research Papers:

Beclin 1 acetylation impairs the anticancer effect of aspirin in colorectal cancer cells

Ting Sun, Liang Ming _, Yunmeng Yan, Yan Zhang and Haikuo Xue

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:74781-74790. https://doi.org/10.18632/oncotarget.20367

Metrics: PDF 903 views  |   HTML 1701 views  |   ?  


Abstract

Ting Sun1,2,*, Liang Ming1,2,*, Yunmeng Yan1,2,*, Yan Zhang1,2 and Haikuo Xue1,2

1Key Clinical Laboratory of Henan Province, Department of Clinical Laboratory, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China

2Department of Medical Laboratory, Zhengzhou University, Zhengzhou 450001, China

*These authors have contributed equally to the work

Correspondence to:

Liang Ming, email: mingliangzzu@163.com

Keywords: aspirin, autophagy, Beclin 1, acetylation, colorectal cancer

Received: May 19, 2017     Accepted: July 25, 2017     Published: August 19, 2017

ABSTRACT

Regular use of aspirin can reduce cancer incidence, recurrence, metastasis and cancer-related mortality. Aspirin suppresses proliferation and induces apoptosis and autophagy in colorectal cancer cells, but the precise mechanism is not clear. In this study, we demonstrated that aspirin induced autophagosome formation in colorectal cancer cells, but autophagic degradation was blocked through aspirin-mediated Beclin 1 acetylation. Blocked autophagic degradation weakened aspirin-induced cell death. Collectively, our findings indicate the dual roles of aspirin on autophagy, and demonstrate a new mechanism by which Beclin 1 acetylation impairs the anticancer effect of aspirin in colorectal cancer cells.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 20367